Stay updated with breaking news from Thilo Schroeder. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Revolution Medicines, Inc. (NASDAQ:RVMD – Get Rating) has been assigned an average rating of “Moderate Buy” from the eight research firms that are currently covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1-year target price among […]
CRANBURY, N.J., Nov. 04, 2022 -- PMV Pharmaceuticals, Inc. , a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53,... | November 4, 2022
Revolution Medicines, Inc. (NASDAQ:RVMD – Get Rating) has been given a consensus recommendation of “Buy” by the seven brokerages that are currently covering the stock, Marketbeat Ratings reports. Three analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1-year price target among brokerages […]
Investment analysts at Bank of America started coverage on shares of Revolution Medicines (NASDAQ:RVMD – Get Rating) in a report released on Friday, The Fly reports. The firm set a “neutral” rating on the stock. RVMD has been the topic of several other research reports. Stifel Nicolaus raised Revolution Medicines from a “hold” rating to […]
Revolution Medicines (NASDAQ:RVMD – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Saturday, Zacks.com reports. According to Zacks, “Revolution Medicines Inc. is a clinical-stage oncology company. It is focused on developing targeted therapies to inhibit elusive frontier targets within notorious cancer pathways. […]